Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Capital Expenditures of $713000.0 for Q1 2026, up 24.22% on a QoQ basis from $574000.0 in Q4 2025, and up 18.05% year-over-year from $604000.0 in Q1 2025.
Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $713000.0 for Q1 2026.
- Quarterly Capital Expenditures rose 18.05% year-over-year to $713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 34.59% YoY) and the FY2025 annual result came in at $2.4 million, up 90.28% from the prior year.
- Capital Expenditures was $713000.0 for Q1 2026 at Bicycle Therapeutics, up from $574000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $9.8 million in Q2 2022 and bottomed at $12000.0 in Q1 2024.
- A 5-year average of $1.5 million and a median of $574000.0 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 5630.41% — and 2024, when it slumped 99.43%.
- Bicycle Therapeutics' Capital Expenditures stood at $1.4 million in 2022, then plunged by 96.48% to $51000.0 in 2023, then jumped by 621.57% to $368000.0 in 2024, then soared by 55.98% to $574000.0 in 2025, then advanced by 24.22% to $713000.0 in 2026.
- Business Quant data shows BCYC's Capital Expenditures at $713000.0 in Q1 2026, $574000.0 in Q4 2025, and $674000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | 713,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 713,000.00 |
| Mar 31, 2026 | 713,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Dec 31, 2023 | 51,000.00 |